Dr Reddy's Q3 Profit Falls 14% Amid North America Sales Decline, Revenue Rises 4%

Dr Reddy's Laboratories reported a 14% year-on-year decline in consolidated net profit to around Rs 1,210 crore for Q3 FY26, despite a 4.4% rise in revenue to approximately Rs 8,727 crore. The profit drop was mainly due to lower sales and price erosion of the cancer drug Lenalidomide in North America, where revenues fell 12%. However, growth in India (19%), Europe (20%), and emerging markets (32%) helped offset this decline. The company emphasized continued focus on strategic priorities including base business growth, pipeline advancement, and operational efficiencies.